docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2025-24-5-79-85docru-364Research ArticleОБЗОРЫREVIEWSГиперандрогенизм в постменопаузе: этиология, диагностика и выбор менопаузальной гормональной терапииPostmenopausal Hyperandrogenism: A Review of Etiology, Diagnosis, and Approaches to Menopausal Hormone Therapyhttps://orcid.org/0000-0001-9081-9041БурчаковД. И.BurchakovD. I.

Бурчаков Денис Игоревич — врач-эндокринолог, ассистент кафедры акушерства и гинекологии ФДПО

Нижний Новгород

Nizhny Novgorod

dr.burchakov@yandex.ruФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииРоссияPrivolzhsky Research Medical UniversityRussian Federation202513112025245ГИНЕКОЛОГИЯ7985Copyright © Бурчаков Д.И., 20252025Бурчаков Д.И.Burchakov D.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/364Цель

Цель. Систематизировать данные, имеющиеся в литературе, об этиологии, диагностике и лечении синдрома гиперандрогении у женщин в постменопаузе.

Основные положения

Основные положения. Гиперандрогенизм в постменопаузе представляет собой клиническую проблему, которую часто игнорируют из-за ошибочного представления о том, что после менопаузы гиперандрогенные состояния встречаются редко. В настоящем обзоре рас­сматриваются этиология, диагностика и лечение избытка андрогенов у женщин в постменопаузе, диагностические и лечебные подходы.

Заключение

Заключение. Гиперандрогенизм в постменопаузе представляет собой сложную клиническую проблему, при которой требуются тщатель­ная дифференциальная диагностика и индивидуальный подход к лечению для обеспечения оптимального ведения пациенток и повыше­ния качества их жизни.

Aim

Aim. To systematize the data available in the literature on the etiology, diagnosis, and treatment of hyperandrogenism syndrome in postmenopausal women.

Key points

Key points. Hyperandrogenism in postmenopause represents a clinical problem that is often overlooked due to the misconception that hyperandrogenic conditions are rare after menopause. This review examines the etiology, diagnosis, and treatment of androgen excess in postmenopausal women, as well as diagnostic and therapeutic approaches.

Conclusion

Conclusion. Hyperandrogenism in postmenopause represents a complex clinical problem that requires careful differential diagnosis and an individualized approach to treatment to ensure optimal patient management and improve quality of their life.

гиперандрогенизмпостменопаузаменопаузальная гормональная терапияhyperandrogenismpostmenopausemenopausal hormone therapyReferencesSoules M.R., Sherman S., Parrott E., Rebar R. et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001;4(4):267–72.Soules M.R., Sherman S., Parrott E., Rebar R. et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001;4(4):267–72.Szmuilowicz E.D., Manson J.E., Rossouw J.E., Howard B.V. et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011;18(6):603–10. DOI: 10.1097/gme.0b013e3182014849Szmuilowicz E.D., Manson J.E., Rossouw J.E., Howard B.V. et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011;18(6):603–10. DOI: 10.1097/gme.0b013e3182014849Zaman A., Rothman M.S. Postmenopausal hyperandrogenism: evaluation and treatment strategies. Endocrinol. Metab. Clin. North Am. 2021;50(1):97–111. DOI: 10.1016/j.ecl.2020.12.002Zaman A., Rothman M.S. Postmenopausal hyperandrogenism: evaluation and treatment strategies. Endocrinol. Metab. Clin. North Am. 2021;50(1):97–111. DOI: 10.1016/j.ecl.2020.12.002Yoldemir T. Postmenopausal hyperandrogenism. Climacteric. 2022;25(2):109–17. DOI: 10.1080/13697137.2021.1915273Yoldemir T. Postmenopausal hyperandrogenism. Climacteric. 2022;25(2):109–17. DOI: 10.1080/13697137.2021.1915273Tutzer M., Winnykamien I., Davila Guardia J., Castelo-Branco C. Hyperandrogenism in post-menopausal women: a diagnosis challenge. Gynecol. Endocrinol. 2014;30(1):23–5. DOI: 10.3109/09513590.2013.850661Tutzer M., Winnykamien I., Davila Guardia J., Castelo-Branco C. Hyperandrogenism in post-menopausal women: a diagnosis challenge. Gynecol. Endocrinol. 2014;30(1):23–5. DOI: 10.3109/09513590.2013.850661Rothman M.S., Wierman M.E. How should postmenopausal androgen excess be evaluated? Clin. Endocrinol. (Oxf.). 2011;75(2):160–4. DOI: 10.1111/j.1365-2265.2011.04040.xRothman M.S., Wierman M.E. How should postmenopausal androgen excess be evaluated? Clin. Endocrinol. (Oxf.). 2011;75(2):160–4. DOI: 10.1111/j.1365-2265.2011.04040.xFabbrocini G., Cantelli M., Masara` A., Annunziata M.C. et al. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int. J. Womens Dermatol. 2018;4(4):203–11. DOI: 10.1016/j.ijwd.2018.05.001Fabbrocini G., Cantelli M., Masara` A., Annunziata M.C. et al. Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review. Int. J. Womens Dermatol. 2018;4(4):203–11. DOI: 10.1016/j.ijwd.2018.05.001Hirschberg A.L. Approach to investigation of hyperandrogenism in a postmenopausal woman. J. Clin. Endocrinol. Metab. 2023;108(5):1243–53. DOI: 10.1210/clinem/dgac673Hirschberg A.L. Approach to investigation of hyperandrogenism in a postmenopausal woman. J. Clin. Endocrinol. Metab. 2023;108(5):1243–53. DOI: 10.1210/clinem/dgac673Keevil B.G., Adaway J. Assessment of free testosterone concentration. J. Steroid Biochem. Mol. Biol. 2019;190:207–11. DOI: 10.1016/j.jsbmb.2019.04.008Keevil B.G., Adaway J. Assessment of free testosterone concentration. J. Steroid Biochem. Mol. Biol. 2019;190:207–11. DOI: 10.1016/j.jsbmb.2019.04.008Unluhizarci K., Hacioglu A., Taheri S., Karaca Z. et al. Idiopathic hirsutism: is it really idiopathic or is it misnomer? World J. Clin. Cases. 2023;11(2):292–8. DOI: 10.12998/wjcc.v11.i2.292Unluhizarci K., Hacioglu A., Taheri S., Karaca Z. et al. Idiopathic hirsutism: is it really idiopathic or is it misnomer? World J. Clin. Cases. 2023;11(2):292–8. DOI: 10.12998/wjcc.v11.i2.292Krug E., Berga S.L. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet. Gynecol. 2002;99(5 pt2):893–7. DOI: 10.1016/s0029-7844(01)01588-5Krug E., Berga S.L. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet. Gynecol. 2002;99(5 pt2):893–7. DOI: 10.1016/s0029-7844(01)01588-5Alsamarai S., Adams J.M., Murphy M.K., Post M.D. et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J. Clin. Endocrinol. Metab. 2009;94(12):4961–70. DOI: 10.1210/jc.2009-0839Alsamarai S., Adams J.M., Murphy M.K., Post M.D. et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J. Clin. Endocrinol. Metab. 2009;94(12):4961–70. DOI: 10.1210/jc.2009-0839Yance V.R.V., Marcondes J.A.M., Rocha M.P., Barcellos C.R.G. et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur. J. Endocrinol. 2017;177(1):93–102. DOI: 10.1530/EJE17-0111Yance V.R.V., Marcondes J.A.M., Rocha M.P., Barcellos C.R.G. et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur. J. Endocrinol. 2017;177(1):93–102. DOI: 10.1530/EJE17-0111Мельниченко Г.А., Дедов И.И., Белая Ж.Е., Рожинская Л.Я. и др. Болезнь Иценко — Кушинга: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы эндокринологии. 2015;61(2):55–77. DOI: 10.14341/probl201561255-77Melnichenko G.A., Dedov I.I., Belaya Zh.E., Rozhinskaya L.Ya. et al. Cushing’s disease: the clinical features, diagnostics, differential diagnostics, and methods of treatment. Problems of Endocrinology. 2015;61(2):55–77. (in Russian). DOI: 10.14341/probl201561255-77Cordera F., Grant C., van Heerden J., Thompson G. et al. Androgensecreting adrenal tumors. Surgery. 2003;134(6):874–80; discussion 880. DOI: 10.1016/s0039-6060(03)00410-0Cordera F., Grant C., van Heerden J., Thompson G. et al. Androgensecreting adrenal tumors. Surgery. 2003;134(6):874–80; discussion 880. DOI: 10.1016/s0039-6060(03)00410-0Ng L., Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 2003;169(1):5–11. DOI: 10.1016/S0022-5347(05)64023-2Ng L., Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol. 2003;169(1):5–11. DOI: 10.1016/S0022-5347(05)64023-2Moreno S., Montoya G., Armstrong J., Leteurtre E. et al. Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery. 2004;136(6):1192–8. DOI: 10.1016/j.surg.2004.06.046Moreno S., Montoya G., Armstrong J., Leteurtre E. et al. Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery. 2004;136(6):1192–8. DOI: 10.1016/j.surg.2004.06.046Walz M.K., Metz K.A., Theurer S., Myland C. et al. Differentiating benign from malignant adrenocortical tumors by a single morphological parameter-a clinicopathological study on 837 adrenocortical neoplasias. Indian J. Surg. Oncol. 2020;11(4):705–10. DOI: 10.1007/s13193-020-01205-4Walz M.K., Metz K.A., Theurer S., Myland C. et al. Differentiating benign from malignant adrenocortical tumors by a single morphological parameter-a clinicopathological study on 837 adrenocortical neoplasias. Indian J. Surg. Oncol. 2020;11(4):705–10. DOI: 10.1007/s13193-020-01205-4Stojadinovic A., Brennan M.F., Hoos A., Omeroglu A. et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod. Pathol. 2003;16(8):742–51. DOI: 10.1097/01.MP.0000081730.72305.81Stojadinovic A., Brennan M.F., Hoos A., Omeroglu A. et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod. Pathol. 2003;16(8):742–51. DOI: 10.1097/01.MP.0000081730.72305.81Wang C., Sun Y., Wu H., Zhao D. et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64(4):567–76. DOI: 10.1111/his.12283Wang C., Sun Y., Wu H., Zhao D. et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64(4):567–76. DOI: 10.1111/his.12283Fleckenstein G., Sattler B., Hinney B., Wuttke W. et al. Androblastoma of the ovary: clinical, diagnostic and histopathologic features. Onkologie. 2001;24(3):286–91. DOI: 10.1159/000055094Fleckenstein G., Sattler B., Hinney B., Wuttke W. et al. Androblastoma of the ovary: clinical, diagnostic and histopathologic features. Onkologie. 2001;24(3):286–91. DOI: 10.1159/000055094Markopoulos M.C., Kassi E., Alexandraki K.I., Mastorakos G. et al. Hyperandrogenism after menopause. Eur. J. Endocrinol. 2015;172(2):R79–91. DOI: 10.1530/EJE-14-0468Markopoulos M.C., Kassi E., Alexandraki K.I., Mastorakos G. et al. Hyperandrogenism after menopause. Eur. J. Endocrinol. 2015;172(2):R79–91. DOI: 10.1530/EJE-14-0468Gui T., Cao D., Shen K., Yang J. et al. A clinicopathological analysis of 40 cases of ovarian Sertoli — Leydig cell tumors. Gynecol. Oncol. 2012;127(2):384–9. DOI: 10.1016/j.ygyno.2012.07.114Gui T., Cao D., Shen K., Yang J. et al. A clinicopathological analysis of 40 cases of ovarian Sertoli — Leydig cell tumors. Gynecol. Oncol. 2012;127(2):384–9. DOI: 10.1016/j.ygyno.2012.07.114Muscat C., Calleja-Agius J. Review on Sertoli — Leydig cell tumours of the ovary. Discov. Med. 2024;36(181):234–47. DOI: 10.24976/Discov.Med.202436181.22Muscat C., Calleja-Agius J. Review on Sertoli — Leydig cell tumours of the ovary. Discov. Med. 2024;36(181):234–47. DOI: 10.24976/Discov.Med.202436181.22Healy D.L., Burger H.G., Mamers P., Jobling T. et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N. Engl. J. Med. 1993;329(21):1539–42. DOI: 10.1056/NEJM199311183292104Healy D.L., Burger H.G., Mamers P., Jobling T. et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N. Engl. J. Med. 1993;329(21):1539–42. DOI: 10.1056/NEJM199311183292104Rey R., Sabourin J.C., Venara M., Long W.Q. et al. Anti-Müllerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors. Hum. Pathol. 2000;31(10):1202–8. DOI: 10.1053/hupa.2000.18498Rey R., Sabourin J.C., Venara M., Long W.Q. et al. Anti-Müllerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors. Hum. Pathol. 2000;31(10):1202–8. DOI: 10.1053/hupa.2000.18498Sekkate S., Kairouani M., Serji B., Tazi A. et al. Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature. World J. Surg. Oncol. 2013;11:142. DOI: 10.1186/1477-7819-11-142Sekkate S., Kairouani M., Serji B., Tazi A. et al. Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature. World J. Surg. Oncol. 2013;11:142. DOI: 10.1186/1477-7819-11-142Carmina E., Guastella E., Longo R.A. Advances in the diagnosis and treatment of PCOS. Curr. Pharm. Des. 2016;22(36):5508–14. DOI: 10.2174/1381612822666160719105808Carmina E., Guastella E., Longo R.A. Advances in the diagnosis and treatment of PCOS. Curr. Pharm. Des. 2016;22(36):5508–14. DOI: 10.2174/1381612822666160719105808Адамян Л.В., Андреева Е.Н., Абсатарова Ю.С., Григорян О.Р. и др. Клинические рекомендации «Синдром поликистозных яичников». Проблемы эндокринологии. 2022;68(2):112–27. DOI: 10.14341/probl12874Adamyan L.V., Andreeva E.N., Absatarova Yu.S., Grigoryan O.R. et al. Clinical guidelines “Polycystic Ovary Syndrome”. Problems of Endocrinology. 2022;68(2):112–27. (in Russian). DOI: 10.14341/probl12874Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98(12):4565–92. DOI: 10.1210/jc.2013-2350Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98(12):4565–92. DOI: 10.1210/jc.2013-2350Cheng V., Doshi K.B., Falcone T., Faiman C. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges. Endocr. Pract. 2011;17(2):e21–5. DOI: 10.4158/EP10138.CRCheng V., Doshi K.B., Falcone T., Faiman C. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges. Endocr. Pract. 2011;17(2):e21–5. DOI: 10.4158/EP10138.CRForslund M., Schmidt J., Brännström M., Landin-Wilhelmsen K. et al. Reproductive hormones and anthropometry: a follow-up of PCOS and controls from perimenopause to older than 80 years. J. Clin. Endocrinol. Metab. 2021;106(2):421–30. DOI: 10.1210/clinem/dgaa840Forslund M., Schmidt J., Brännström M., Landin-Wilhelmsen K. et al. Reproductive hormones and anthropometry: a follow-up of PCOS and controls from perimenopause to older than 80 years. J. Clin. Endocrinol. Metab. 2021;106(2):421–30. DOI: 10.1210/clinem/dgaa840Sharma A., Kapoor E., Singh R.J., Chang A.Y. et al. Diagnostic thresholds for androgen-producing tumors or pathologic hyperandrogenism in women by use of total testosterone concentrations measured by liquid chromatography-tandem mass spectrometry. Clin. Chem. 2018;64(11):1636–45. DOI: 10.1373/clinchem.2018.290825Sharma A., Kapoor E., Singh R.J., Chang A.Y. et al. Diagnostic thresholds for androgen-producing tumors or pathologic hyperandrogenism in women by use of total testosterone concentrations measured by liquid chromatography-tandem mass spectrometry. Clin. Chem. 2018;64(11):1636–45. DOI: 10.1373/clinchem.2018.290825Meun C., Franco O.H., Dhana K., Jaspers L. et al. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study. J. Clin. Endocrinol. Metab. 2018;103(4):1622–30. DOI: 10.1210/jc.2017-02421Meun C., Franco O.H., Dhana K., Jaspers L. et al. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study. J. Clin. Endocrinol. Metab. 2018;103(4):1622–30. DOI: 10.1210/jc.2017-02421Hirschberg A.L. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health. (Lond.). 2009;5(5):529–40; quiz 541– 2. DOI: 10.2217/whe.09.39Hirschberg A.L. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health. (Lond.). 2009;5(5):529–40; quiz 541– 2. DOI: 10.2217/whe.09.39Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 2012;33(6):981–1030. DOI: 10.1210/er.2011-1034Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 2012;33(6):981–1030. DOI: 10.1210/er.2011-1034Xing C., Zhang J., Zhao H., He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. Int. J. Womens Health. 2022;14:91–105. DOI: 10.2147/IJWH.S344542Xing C., Zhang J., Zhao H., He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. Int. J. Womens Health. 2022;14:91–105. DOI: 10.2147/IJWH.S344542Speiser P.W., Arlt W., Auchus R.J., Baskin L.S. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical practice guideline. J. Clin. Endocrinol. Metab. 2018;103(11):4043–88. DOI: 10.1210/jc.2018-01865Speiser P.W., Arlt W., Auchus R.J., Baskin L.S. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical practice guideline. J. Clin. Endocrinol. Metab. 2018;103(11):4043–88. DOI: 10.1210/jc.2018-01865Ishii T., Kashimada K., Amano N., Takasawa K. et al. Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision). Clin. Pediatr. Endocrinol. 2022;31(3):116–43. DOI: 10.1297/cpe.2022-0009Ishii T., Kashimada K., Amano N., Takasawa K. et al. Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision). Clin. Pediatr. Endocrinol. 2022;31(3):116–43. DOI: 10.1297/cpe.2022-0009Carmina E., Dewailly D., Escobar-Morreale H.F., Kelestimur F. et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum. Reprod. Update. 2017;23(5):580–99. DOI: 10.1093/humupd/dmx014Carmina E., Dewailly D., Escobar-Morreale H.F., Kelestimur F. et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum. Reprod. Update. 2017;23(5):580–99. DOI: 10.1093/humupd/dmx014Azziz R., Sanchez L.A., Knochenhauer E.S., Moran C. et al. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 2004;89(2):453–62. DOI: 10.1210/jc.2003-031122Azziz R., Sanchez L.A., Knochenhauer E.S., Moran C. et al. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 2004;89(2):453–62. DOI: 10.1210/jc.2003-031122Meczekalski B., Szeliga A., Maciejewska-Jeske M., Podfigurna A. et al. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol. Endocrinol. 2021;37(8):677–82. DOI: 10.1080/09513590.2021.1903419Meczekalski B., Szeliga A., Maciejewska-Jeske M., Podfigurna A. et al. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol. Endocrinol. 2021;37(8):677–82. DOI: 10.1080/09513590.2021.1903419Elhassan Y.S., Idkowiak J., Smith K., Asia M. et al. Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women. J. Clin. Endocrinol. Metab. 2018;103(3):1214–23. DOI: 10.1210/jc.2017-02426Elhassan Y.S., Idkowiak J., Smith K., Asia M. et al. Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women. J. Clin. Endocrinol. Metab. 2018;103(3):1214–23. DOI: 10.1210/jc.2017-02426Cussen L., McDonnell T., Bennett G., Thompson C.J. et al. Approach to androgen excess in women: clinical and biochemical insights. Clin. Endocrinol. (Oxf.). 2022;97(2):174–86. DOI: 10.1111/cen.14710Cussen L., McDonnell T., Bennett G., Thompson C.J. et al. Approach to androgen excess in women: clinical and biochemical insights. Clin. Endocrinol. (Oxf.). 2022;97(2):174–86. DOI: 10.1111/cen.14710Nieman L.K., Biller B.M.K., Findling J.W., Newell-Price J. et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008;93(5):1526–40. DOI: 10.1210/jc.2008-0125Nieman L.K., Biller B.M.K., Findling J.W., Newell-Price J. et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008;93(5):1526–40. DOI: 10.1210/jc.2008-0125Fleseriu M., Auchus R., Bancos I., Ben-Shlomo A. et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847–75. DOI: 10.1016/S2213-8587(21)00235-7Fleseriu M., Auchus R., Bancos I., Ben-Shlomo A. et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847–75. DOI: 10.1016/S2213-8587(21)00235-7Зайдиева Я.З. Гиперандрогения у женщин в постменопаузе: клинические формы и дифференциальная диагностика. Российский вестник акушера-гинеколога. 2013;13(4):89–94.Zaĭdieva Ia.Z. Hyperandrogenism in postmenopausal women: clinical forms and differential diagnosis. Russian Bulletin of Obstetrician-Gynecologist. 2013;13(4):89–94. (in Russian)Zotter Z., Veszeli N., Csuka D., Varga L. et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet. J. Rare Dis. 2014;9:205. DOI: 10.1186/s13023-014-0205-6Zotter Z., Veszeli N., Csuka D., Varga L. et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet. J. Rare Dis. 2014;9:205. DOI: 10.1186/s13023-014-0205-6Vorona E., Nieschlag E. Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding. Minerva Endocrinol. 2018;43(4):476–88. DOI: 10.23736/S0391-1977.18.02810-9Vorona E., Nieschlag E. Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding. Minerva Endocrinol. 2018;43(4):476–88. DOI: 10.23736/S0391-1977.18.02810-9Azziz R., ed. Androgen excess disorders in women. Humana Press; 2006. 488 p.Azziz R., ed. Androgen excess disorders in women. Humana Press; 2006. 488 p.Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И. и др. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ РКО, РОАГ, РАЭ, ЕАТ, РАФ. Проблемы эндокринологии. 2023;69(5):115–36. DOI: 10.14341/probl13394Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I. et al. Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Problems of Endocrinology. 2023;69(5):115– 36. (in Russian). DOI: 10.14341/probl13394Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(suppl.1):3–63. DOI: 10.1080/13697130500148875Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(suppl.1):3–63. DOI: 10.1080/13697130500148875

The authors declare that there are no conflicts of interest present.